30 closest matches · ranked by relevance
Graft Versus Host Disease
Primary: Maximum Tolerated Dose of High-dose Cyclophosphamide as Determined by Number of Participants Who Tolerated Each Dose of Cyclophosphamide — 4; 4; 2 Participants
Graft vs Host Disease
Primary: Number of Participants With the Ability to Successfully Taper Prednisone to a Dose Lower Dose. — 14 Participants
Graft Versus Host Disease · Recurrent Adult Acute Lymphoblastic Leukemia
Primary: Mean Cumulative Prednisone Dose (mg/kg) Over 42 Days From the Start of Treatment — 22.2; 27.1; 38.4; 41.3 milligrams per kilogram — p=0.08
Graft vs Host Disease
Primary: Clinical Activity — 4; 4 participants
Graft vs Host Disease
Primary: Overall Response (Complete Response + Partial Response + Other) — 7; 2; 0; 0 participants
Graft Versus Host Disease
Primary: Response Rate — 20 percentage of participants
Graft-versus-Host Disease · Immune System Disorders
Primary: GVHD-free Survival — 60; 69; 59; 47 participants
Graft vs Host Disease · Immune System Disorders
Primary: Number of Complete Response (CR) at Day 28 of Therapy — 12; 27; 25; 16 participants
Chronic Graft Versus Host Disease
Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) — 3; 3; 10; 0 participants
Graft-Versus-Host Disease
Primary: Phase I: Maximum Tolerated Dose (MTD) in Milligrams — 5 MTD of oral LBH589 in milligrams
Graft-versus-host Disease (GVHD)
Primary: Overall Response Rate (ORR) at Day 28 — 19; 7; 13 Participants
Acute Graft vs Host Disease · Allogeneic Bone Marrow Transplantation · Adverse Effects
Primary: Number of Participants Who Were Responders (CR, VGPR, or PR) on Day 28 With Low Cumulative Steroid Exposure — 41 Participants
Corticosteroid Refractory Acute Graft vs Host Disease
Primary: Overall Response Rate (ORR) at Day 28 — 62.3; 39.4 Percentage of participants — p=<.0001
Acute Graft Versus Host Disease
Primary: Number of Participants With Complete Response (CR) — 34 Participants
Chronic GVHD
Primary: Proportion of Participants With Treatment Success — 33; 35; 33; 37 Participants — p=0.63
Chronic Graft-versus-host Disease
Primary: Rate of Complete Response of cGVHD to Treatment. — 84 percentage of patients — p=<0.5
Low Risk Acute Graft-versus-host Disease · Graft-versus-host-disease · GVHD
Primary: Number of Patients Who Achieve CR or PR by Day 28 of Treatment — 62 Participants
Graft Versus Host Disease
Primary: Number of Participants Experiencing Treatment Success — 8 Participants
Graft vs Host Disease
Primary: Percentage of Patients That Respond to Treatment — 65 percentage of patients
Chronic Graft Versus Host Disease
Primary: Overall Response Rate at Week 16 (4 Weeks After the End of Treatment) — 88.9; 80.0 percentage of participants
Chronic Graft-Versus-Host Disease · Immune System Diseases
Primary: Number of Participants With Complete or Partial Remission of Chronic Graft Versus Host Disease After a First Line Treatment With Arsenic Trioxide — 15 Participants
Graft vs Host Disease
Primary: Clinical Response of Patients With Refractory Chronic GVHD Based on the Working Group Report 2006. — 100; 78; 80 percentage of participants
Graft Versus Host Disease
Primary: The Maximum Tolerated Dose and Toxicity Profile of an 8 Week Course of IL-2 in Patients With cGVHD and an Inadequate Response to Steroids. — 1 million IU/m2/day
Oral Chronic Graft-versus-host Disease
Primary: The Clinical Efficacy of Topical Steroid and Topical Tacrolimus Therapies for the Treatment of Oral cGHVD. — 15; 3; 11; 2 participants
Grade B aGVHD · Grade C aGVHD · Grade D aGVHD
Primary: Overall Response Rate (ORR) at Day 28 Post Initiation of Therapy — 69.1 percentage of participants — p=0.0003
Graft-versus-host Disease (GVHD)
Primary: Overall Response Rate Based on Center for International Blood and Marrow Transplant Research (CIBMTR) Response Index — 74.0; 66.4 Percentage of Participants — p=0.0782
Acute Graft Versus Host Disease
Primary: The Percentage of Patients Who Progress Within 28 Days of Initiation of Etanercept Treatment — 29 percentage of patients
Graft Versus Host Disease (GVHD)
Primary: Overall Response Rate (ORR) to Acute Graft-versus-Host Disease (GVHD) Treatment — 60.0; 45.1 percentage of participants — p=0.034
Chronic GVHD
Primary: Fraction of Participants With an Overall Response Rate (Complete Response [CR] + Partial Response [PR]) Reported With an 80% Confidence Interval at 6 Months — 0; 0.1667…
Acute Leukemia · Chronic Myelogenous Leukemia · Myelodysplasia
Primary: Percentage of Participants With GVHD/Relapse or Progression-free Survival (GRFS) — 35.5; 27.2; 44.1 percentage of participants